 Athira Pharma changed its name last year to reflect its focus on regenerative medicine. Now, its snagged 85 million to advance those medicines, which includes bankrolling a phase 23 trial in Alzheimers for its lead asset, designed to restore the lost neural connections in the brain or spur the growth of new ones. 